Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Bemiltenase alfa in Hemophilia B: NCT05619926 Clinical Landscape Report 2026
9 min read
Bemiltenase alfa in Hemophilia B: NCT05619926 Clinical Landscape Report 2026
15 October 2026
NCT05619926 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bexotegrast in Idiopathic Pulmonary Fibrosis: NCT05621252 Clinical Landscape Report 2026
9 min read
Bexotegrast in Idiopathic Pulmonary Fibrosis: NCT05621252 Clinical Landscape Report 2026
15 October 2026
NCT05621252 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fecal microbiota(Mikrobiomik Healthcare) in Metabolic Dysfunction Associated Steatohepatitis: NCT05622526 Clinical Landscape Report 2026
9 min read
Fecal microbiota(Mikrobiomik Healthcare) in Metabolic Dysfunction Associated Steatohepatitis: NCT05622526 Clinical Landscape Report 2026
15 October 2026
NCT05622526 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Osivelotor in Anemia, Sickle Cell: NCT05632354 Clinical Landscape Report 2026
9 min read
Osivelotor in Anemia, Sickle Cell: NCT05632354 Clinical Landscape Report 2026
15 October 2026
NCT05632354 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Berberine Ursodeoxycholate in Fibrosis, Liver: NCT05623189 Clinical Landscape Report 2026
9 min read
Berberine Ursodeoxycholate in Fibrosis, Liver: NCT05623189 Clinical Landscape Report 2026
15 October 2026
NCT05623189 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mitiperstat in Metabolic Dysfunction Associated Steatohepatitis: NCT05638737 Clinical Landscape Report 2026
9 min read
Mitiperstat in Metabolic Dysfunction Associated Steatohepatitis: NCT05638737 Clinical Landscape Report 2026
15 October 2026
NCT05638737 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
ZS-801 in Hemophilia B: NCT05641610 Clinical Landscape Report 2026
9 min read
ZS-801 in Hemophilia B: NCT05641610 Clinical Landscape Report 2026
15 October 2026
NCT05641610 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
ZS-801 in Hemophilia B: NCT05630651 Clinical Landscape Report 2026
9 min read
ZS-801 in Hemophilia B: NCT05630651 Clinical Landscape Report 2026
15 October 2026
NCT05630651 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Tocilizumab in Acute Chest Syndrome: NCT05640271 Clinical Landscape Report 2026
9 min read
Tocilizumab in Acute Chest Syndrome: NCT05640271 Clinical Landscape Report 2026
15 October 2026
NCT05640271 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ertugliflozin pidolate in Fibrosis, Liver: NCT05644717 Clinical Landscape Report 2026
9 min read
Ertugliflozin pidolate in Fibrosis, Liver: NCT05644717 Clinical Landscape Report 2026
15 October 2026
NCT05644717 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Recombinant Human Coagulation Factor VIIa-Fc Fusion Protein (Jiangsu Gensciences) in Hemophilia B: NCT05651061 Clinical Landscape Report 2026
9 min read
Recombinant Human Coagulation Factor VIIa-Fc Fusion Protein (Jiangsu Gensciences) in Hemophilia B: NCT05651061 Clinical Landscape Report 2026
15 October 2026
NCT05651061 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ravulizumab-CWVZ in Myasthenia Gravis: NCT05644561 Clinical Landscape Report 2026
9 min read
Ravulizumab-CWVZ in Myasthenia Gravis: NCT05644561 Clinical Landscape Report 2026
15 October 2026
NCT05644561 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →